Retatrutide 30 mg is the extended-run lyophilised vial supplied by BuyRetaUK — the presentation of choice when a single reconstitution needs to serve a longer or larger in-vitro programme with a standardised working concentration.
Retatrutide 30 mg is a 30-milligram lyophilised research-peptide vial released to ≥99% HPLC-UV with mass-spectrometric identity. It is the extended-run presentation in the BuyRetaUK ladder, chosen when a single reconstitution needs to feed a sustained multi-week workflow at a fixed concentration.
Retatrutide 30 mg is a lyophilised vial containing 30 milligrams of Retatrutide (LY3437943), a synthetic triple receptor agonist. In the BuyRetaUK range it occupies the extended-run slot — the strength typically chosen when a laboratory wants one reconstitution to underwrite a sustained multi-week experimental programme without switching between vial batches.
For compound context — receptor pharmacology, structure and the research landscape around Retatrutide — see the cornerstone What is Retatrutide? guide.
Step down to Retatrutide 20 mg if the study will not fully consume a 30 mg reconstitution; step up to Retatrutide 40 mg for the largest sustained programmes where one reconstitution should carry the entire run. All strengths share the same release specification — the choice is one of programme scale. Full ladder view in the Strengths Hub.
Every vial ships with a batch-specific COA · UK dispatch
30 mg vials ship with a batch-specific Certificate of Analysis in the same format as every other Retatrutide strength. Batch numbers on the vial label resolve to the corresponding COA in the verification library. Field-by-field explanation lives in the Certificate of Analysis guide.
30 mg vials are released against the same ≥99% HPLC-UV specification with ESI-MS identity confirmation as every other strength in the range. Full method context, impurity profiling and interpretation live in the Retatrutide Purity reference.
With 30 mg reconstitutions, freezer capacity and aliquot labelling matter more — plan the freezer grid before reconstitution so every aliquot has a mapped experimental slot. Storage temperatures and freeze-thaw framework are identical to smaller vials; see the Retatrutide Storage guide for full detail.
Reverse-phase HPLC quantifies purity as a percentage of total peak area. Release specification: ≥99%.
Learn more →Certificate of AnalysisEvery batch ships with a batch-specific COA reporting identity, purity and appearance.
Learn more →Laboratory QualityIndependent third-party analysis, temperature-controlled UK storage and full batch traceability.
Learn more →Batch VerificationCross-reference the batch number printed on your vial against our live COA library.
Learn more →Storage StandardsLyophilised at 2–8°C protected from light. Reconstituted stability ~30 days at 2–8°C.
Learn more →Sketch aliquot layout, labelling and expected timepoints before opening the vial.
Fix a diluent volume for every 30 mg vial so downstream comparisons stay clean.
Ensure freezer volume can accommodate the aliquot count without displacing other stock.
Cross-reference the vial batch number against the COA before reconstituting.
30 mg fits sustained studies that consume more peptide than a 20 mg vial can serve from a single reconstitution, but do not yet justify moving to 40 mg. It is also chosen when a laboratory standardises on one vial strength across a multi-week programme to keep concentration and batch variables stable.
Reconstituting 30 mg in 3 mL of bacteriostatic water yields 10 mg/mL; in 6 mL yields 5 mg/mL; in 15 mL yields 2 mg/mL. Any target concentration can be modelled in the reconstitution calculator.
Yes — absolute price typically scales sub-linearly, so a 30 mg vial usually offers a lower per-milligram cost than 20 mg while retaining an identical release specification. Current per-strength pricing lives on the product page.
A 30 mg reconstitution generally yields 6–15 useful aliquots depending on assay dose. Prepare a labelled freezer grid before reconstitution so each aliquot maps to a defined experimental timepoint and no aliquot is thawed twice.
40 mg is the highest available presentation and best fits the largest, longest programmes. 30 mg is often preferred when a laboratory wants extended-run economics without committing to the largest single reconstitution volume in the range.
No. Every BuyRetaUK Retatrutide vial, including 30 mg, is supplied for in-vitro laboratory research only and is not intended for human or veterinary administration.
Peer-reviewed citations are added as each article is expanded. See our editorial standards for our sourcing and accuracy commitments.
The BuyRetaUK editorial team publishes laboratory-focused reference content on research peptides, analytical methods and Certificates of Analysis. All articles are written for in-vitro research contexts only.
View profile →Every editorial article is reviewed against our accuracy commitment and quality-assurance checklist before publication. Named reviewer profiles are added as our reviewer network expands.
View profile →Every article follows a documented editorial process — sourcing, scientific review, update cadence and correction policy — so researchers can rely on what we publish.
Read the full editorial standards →Educational first. Each step is optional — start wherever you are in your research.
Compound overview, receptor profile and research framing.
Triple vs dual incretin agonist — how they differ.
Triple agonist vs single GLP-1 agonist.
How to verify identity, purity and batch quality.
Every retatrutide variant with lab data.
Solvent volume and dose-per-unit calculator.
Triple vs dual incretin agonist — receptor profile and research framing.
View comparison →Side by sideTriple agonist vs single GLP-1 — class, mechanism and lab context.
View comparison →Multi-compoundAll GLP-1 / GIP / glucagon research compounds in one place.
View comparison →A laboratory overview of retatrutide (LY3437943) — a triple agonist research peptide acting on the GLP-1, GIP and glucagon receptors.
6 min read →Storage & HandlingHow to store lyophilised research peptides and reconstitute them correctly for laboratory use.
4 min read →RetatrutideBackground on retatrutide in the academic literature — receptor pharmacology, study context and analytical handling.
8 min read →Product ComparisonsSide-by-side comparison of retatrutide and tirzepatide across receptor profile, research context and analytical considerations.
5 min read →Every batch of Retatrutide ships with a third-party HPLC and mass-spec Certificate of Analysis. Browse the live COA library to verify your lot.
Long-term frozen storage (-20°C) is acceptable for lyophilised vials, but routine refrigerated storage at 2–8°C is sufficient for typical research timelines.
Read: Storage & Reconstitution →No. Retatrutide is supplied strictly for laboratory research and is not approved for human or veterinary administration.
Read: What is Retatrutide? →In published research it has been characterised as a triple agonist acting on the GLP-1, GIP and glucagon receptors.
Read: What is Retatrutide? →Lyophilised vials are stored at 2–8°C, protected from light. Once reconstituted with bacteriostatic water, store refrigerated and use within 30 days.
Read: What is Retatrutide? →
